Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound

Print E-mail
By Josh Gee   
Wednesday, 19 November 2014 09:56

When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses.

Read more...
 

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak

Print E-mail
By Steve Brozak   
Friday, 14 November 2014 00:22
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report.
Read more...
 

Enanta Pharmaceutical's review slated for late December

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 11:27

Enanta Pharmaceutical, Inc, (NASDAQ:ENTA) recently announced that their collaborator Abbvie’s New Drug Application for an interferon-free regimen had been acknowledged by U.S. Food and Drug Administration. The NDA for acceptance of this regimen was submitted on April 21, 2014. The BioMedReports FDA Calendar shows a date for review on December 21, 2014.

Read more...
 

Pozen’s PA8140/PA32540 Tablets Get Another Look

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:20

As you may know, POZEN Inc. (NASDAQ: POZN), gets another chance for a New Drug Application reevaluation after their previous NDA was not accepted due to the issues indicated at some stage in an inspection of the production facility creating an essential constituent necessary for the production of the firm's PA8140/PA32540 Tablets.

Read more...
 

Closer Look: Cubist Pharmaceuticals' New Antibiotic Contender

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:14

Cubist Pharmaceuticals (NASDAQ:CBST) previously announced that new antibiotic Ceftolozane has a new drug application which is being out through the steps by the Food and Drug Administration under a priority review, moreover, the FDA has issued a drug user fee act (PDUFA) date of December 21, 2014.

Read more...
 

BiorCryst’s Peramivir PDUFA Date Approaching

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 09:05

 As you may know, BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) submitted New Drug Application with U.S Food and Drug Administration (FDA) for approval of Peramivir in U.S. The same drug has already been approved in Korea and Japan for treatment of acute influenza.
Read more...
 

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound, but Investors Remain Enchanted by Big Pharma's Solid Returns

Print E-mail
By The Life Science Report   
Monday, 10 November 2014 08:55
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted.
Read more...
 

Huge Growth Delivered in Very Small Packages: SeeThruEquity's Ajay Tandon and Brandon Primack

Print E-mail
By The Life Science Report   
Wednesday, 05 November 2014 23:42
Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very small companies.
Read more...
 

Q&A with Cell Source CEO, Itamar Shimrat – transition from preclinical to human clinical trials

Print E-mail
By M.E.Garza   
Wednesday, 05 November 2014 08:35

Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections.

Read more...
 

Which Small-Cap Biotech Has The Most Comprehensive, Yet Undervalued Immunotherapy Platform In Development?

Print E-mail
By David Ibrahim, MarketScanners   
Monday, 03 November 2014 23:20

icon_closerlookThe National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research. While the larger research entities like NCI get all the press coverage and media attention, it's the smaller highly specialized organizations working behind the scenes that are the real heroes.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 48

Newsletter

BioMedReports We here at http://t.co/Gh1Gn5YCuz wish you and your family a safe and Happy Thanksgiving. http://t.co/FCbSNKrVuj
BioMedReports This is how a living, beating heart is grown from stem cells. http://t.co/MLrFZyj3la
BioMedReports FDA Orders New Label For Biogen Idec's MS Drug; Exact Sciences Announces Final Payment Decision for Cologuard®... http://t.co/LwIBwixMkt